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Abstract
Background: dual therapy with aspirin and clopidogrel
increases the risk of gastrointestinal bleeding. there-
fore, co-therapy with a proton pump inhibitor (PPI) is
recommended by most guidelines. However, there are
warnings against combining PPIs with clopidogrel be-
cause  of  their  interactions  with  cytochrome  P450
isoenzyme 2C19 (CYP2C19).
Methods: the effects of the combined or separate in-
take of 20 mg of omeprazole and 75 mg of clopido-
grel on the clopidogrel-induced inhibition of platelet
aggregation  were  measured  in  four  healthy  subjects
whose  CYP2C19 exon  sequences  were  determined.
the effects of co-therapy with 10 mg of rabeprazole
were also examined.
Results: two subjects showed the wild-type CYP2C19
sequence. the concurrent intake of omeprazole had
no effect on clopidogrel-induced platelet inhibition in
these subjects. two subjects were heterozygous for the
*2  allele,  with  predicted  reduced  CYP2C19 activity.
one of them was a clopidogrel non-responder. In the
second heterozygous subject, omeprazole co-therapy
reduced the clopidogrel anti-platelet effect when taken
simultaneously or separately . However, the simultane-
ous intake of rabeprazole did not reduce the clopido-
grel effect.
Conclusion: the clopidogrel–PPI interaction does not
seem to be a PPI class effect. Rabeprazole did not af-
fect  the  clopidogrel  effect  in  a  subject  with  a  clear
omeprazole–clopidogrel interaction. the separate in-
take of PPI and clopidogrel may not be sufficient to
prevent their interaction.
Key  words: Proton  Pump  Inhibitors,  drug  Interac-
tions, Clopidogrel, omeprazole, Rabeprazole
IntRoduCtIon
dual anti-platelet therapy with aspirin and a thienopy-
ridine  (mainly  clopidogrel)  is  recommended  in  the
guidelines of national and international cardiology so-
cieties  for  patients  with  acute  coronary  syndrome
and/or  percutaneous  coronary  interventions.  this
combination is usually prescribed for up to one year.
therefore,  the  number  of  patients  treated  with  this
regimen is high.
unfortunately, this combination increases the risk
of  upper  gastrointestinal  bleeding.  therefore,  most
guidelines recommend that patients prescribed aspirin
plus clopidogrel should also receive a proton pump in-
hibitor  (PPI)  to  reduce  the  risk  of  gastrointestinal
bleeding, e.g., the uS guidelines [1] and the german
guidelines [2].
In the last two years, pharmacological studies have
reported  an  interaction  between  clopidogrel  and
omeprazole.  Subjects  taking  both  drugs  together
showed a reduction in the clopidogrel-induced inhibi-
tion of platelet aggregation [3, 4].
the  pharmacological  basis  of  this  phenomenon
seems to be the competitive inhibition of cytochrome
metabolism,  especially  CYP  P450  2C19  (CYP2C19).
Clopidogrel is a pro-drug requiring a two-step oxida-
tion  by  hepatic  cytochromes,  including  CYP2C19,
3A/5, 1A2, 2B6, and 2C9, to generate its active thiol
metabolite [5]. the key step in its conversion to the
active  anti-thrombotic  agent  is  performed  by
CYP2C19. However, all PPIs are metabolized to inac-
tive metabolites by CYP2C19 or other cytochromes to
varying  degrees  [6,  7].  Polymorphisms  of  the  cy-
tochromes  may  play  important  roles  in  a  patient’s
pharmacological  response  to  clopidogrel  treatment
and the pharmacological interactions of this drug [8,
9].
data-bank analyses and retrospective cohort studies
[10-13]  have  demonstrated  an  increased  risk  of  ad-
verse  cardiac  events  in  clopidogrel-treated  patients
who  also  take  PPIs  (mainly  omeprazole).  However,
subgroup analyses of randomized controlled trials [14,
15] and other studies [16, 17] have not confirmed the
adverse effects of PPI co-therapy. only one random-
ized controlled study has so far addressed this topic
(CogEnt). unfortunately, this trial was stopped ear-
ly, after the sponsor Cogentus Pharmaceuticals (Palo
alto, Ca, uSa) declared bankruptcy. the first reports
from this study did not show evidence of a clinically
relevant drug interaction [18].
based  in  this  uncertainty,  both  the  uS  Food  and
drug administration (Fda) and the European Medi-
cines agency (EMEa) have warned that omeprazole
should not be combined with clopidogrel unless “ab-
solutely necessary” (EMEa). the Fda warning also
included esomeprazole. these warnings of the Fda
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problem for physicians treating patients who require
dual therapies.
based on their mode of action via the irreversible
inhibition of platelet and parietal cell functions, both
clopidogrel and PPI are very potent and long-acting
drugs.  the  active  metabolite  of  clopidogrel  irre-
versibly  inhibits  the  platelet  adenosine  diphosphate
(adP) P2Y12 receptor through an inactivating disul-
fide bond, whereas PPIs irreversibly inhibit the proton
pumps of parietal cells. However, the plasma half lives
of both clopidogrel and PPIs are less than two hours.
therefore, several authors have recommended that the
intake of the two drugs be separated to reduce the risk
of their interaction [19, 20]. However, no data have
yet been published on the efficacy of this regimen in
preventing  the  clinically  relevant  interaction  of  PPI
and clopidogrel.
other  recommendations  have  suggested  the  pre-
scription of a PPI other than omeprazole in combina-
tion with clopidogrel [21, 22]. However, few data are
so  far  available  on  the  differences  between  various
PPIs  in  their  potential  interactions  with  clopidogrel
activation. Pantoprazole [22-24] and esomeprazole [23,
24] but not lansoprazole [25] seem to have little or no
pharmacological effect on the activation of clopido-
grel.
We  studied  the  effects  of  both  the  separation  of
omeprazole and clopidogrel intake on platelet inhibi-
tion and the use of the PPI rabeprazole in a co-thera-
py with clopidogrel in four subjects whose CYP2C19
gene sequences were determined.
MatERIal and MEtHodS
SubJECtS
Four healthy volunteers were studied. the study was
conducted in a manner consistent with ethical princi-
ples based on the declaration of Helsinki. Written in-
formed consent was obtained from all study partici-
pants before study entry.
MEdICatIon and StudY PRotoCol
after the baseline (day 0) platelet function of all sub-
jects was measured, 75 mg of clopidogrel was given in
the morning before breakfast for seven days without
an  initial  loading  dose.  on  day  7,  two  hours  after
clopidogrel intake, a blood sample was drawn for the
analysis of platelet function, and 20 mg of omepra-
zole (antra MuPS, astrazeneca gmbH, Wedel, ger-
many)  was  taken.  For  the  next  six  days,  75  mg  of
clopidogrel and 20 mg of omeprazole were taken to-
gether before breakfast. after seven days of the com-
bined intake of clopidogrel and omeprazole, another
blood sample was taken two hours after the adminis-
tration of the medication (day 14). For the next seven
days,  clopidogrel  was  taken  before  breakfast  and
omeprazole was taken before dinner (the intake of the
two drugs was separated by 12 hours). a blood sample
was taken in the morning after the separated intake of
clopidogrel and omeprazole (day 21) for seven days.
no omeprazole was taken in the evening of day 21.
Starting day 22, the subjects took clopidogrel and 10
mg of rabeprazole together before breakfast. again,
blood was drawn after seven days, two hours after the
intake of the medication (day 28).
Study endpoints: non-responders to clopidogrel were
discharged  from  the  study  after  the  first  week  of
clopidogrel  intake.  Subjects  with  no  reduction  in
platelet inhibition in response to the co-therapy with
clopidogrel and omeprazole were not investigated fur-
ther.
aggREgoMEtRY
adP-induced aggregometry is a widely used method
of  measuring  responsiveness  to  clopidogrel.  Whole-
blood aggregation was determined with an impedance
aggregometer (Multiplate analyzer, dynabyte gmbH,
Munich, germany). the system detects the change in
electrical impedance attributed to the adhesion and ag-
gregation of platelets on two independent pairs of sil-
ver-coated, highly conductive copper wires (length 3.2
mm) in the test cuvette. therefore, two measurements
are obtained as an internal control. For the analysis,
300 ﾵl of whole blood anti-coagulated with hirudin
(200 u/ml, dynabyte gmbH) and 300 ﾵl of 0.9%
naCl was stirred at 37 ﾰC for 3 min in a single-use test
cuvette, and adP (6.4 ﾵmol/l; dynabyte gmbH) was
added. Pipetting was performed with an attached elec-
tronic  pipette.  the  increase  in  electrical  impedance
was recorded continuously for 6 min. the areas under
the curves (auC) of the aggregation tracings are ex-
pressed as the mean values of two independent deter-
minations. the results measured with the Multiplate
analyzer were reproducible, with less than 6% vari-
ability  [26].  the  reference  range  of  the  test  was
53–122 auC [u]. 
gEnotYPIng
dna  was  extracted  from  Edta  blood  using  the
Flexigene  dna  isolation  kit  (Qiagen,  Hilden,  ger-
many). all nine coding exons and the flanking regions
of  the  CYP2C19 gene  (genbank:  nt_030059.13)
were amplified with a standard PCR, and analysed by
direct dna sequencing with bigdye v1.1 on an abI
Prism  3130  avant  Xl  (applied  biosystems,  Foster
City, Ca, uSa). to describe the mutations, we applied
the  nomenclature  used  by  the  CYPalleles  data  base
(http://www.cypalleles.ki.se;  genbank  M61854.1).
the primer sequences are available upon request. the
gene sequences were analysed with the software Muta-
tion Surveyor V3.10 (Softgenetics llC, State College,
Pa, uSa).
RESultS
two subjects were found to carry the wild-type allele
(allele *1) of CYP2C19 (subject #1 and #2). the oth-
er two subjects (#3 and #4) were heterozygous for the
mutations c.681g>a; p.Pro227Pro, and thus carried
the alleles *1/*2 (table 1). no other reduced-function
CYP2C19 allele was observed in this study group. Re-
duced CYP2C19 function was predicted for the sub-
jects with the CYP2C19 wt/*2 genotype [8, 9].
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normal.  the  clopidogrel-induced  inhibition  of
platelet  function  was  not  influenced  by  the  co-
therapy with omeprazole (table 2, Fig. 1). therefore,
according to the protocol, not further tests were per-
formed.
In subject #2, the platelet function was inhibited by
clopidogrel  mono-therapy,  and  platelet  function  was
normalized  when  clopidogrel  and  omeprazole  were
taken together (value 58 u). because the subject suf-
fered from diarrhoea on days 5 and 6 of the combined
intake  (presumably  viral  enteritis),  this  part  of  the
study was repeated after his recovery and no effect of
omeprazole co-medication was observed on clopido-
grel-induced platelet inhibition (10 u; data shown in
table 2).
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Table 1. Subject characteristics and CYP2C19 allele status
Subject  Sex Age  CYP2C19 alleles Predicted CYP2C19 function
1 male 58 wt/wt normal
2 male 51 wt/wt normal
3 female 28 wt/*2 reduced
4 female 32 wt/*2 reduced
Table  2.  adP-induced  platelet  aggregation  in  four  subjects  treated  with  clopidogrel  with  and  without  PPI  co-therapy. 
the reference range of the test was 53–122 u.
Clopidogrel intake inhibits adP-induced platelet aggregation in subjects showing the expected clopidogrel effect. normal
platelet function under clopidogrel mono-therapy represents a non-responder status. the normalization of platelet function by
co-therapy with clopidogrel and PPI after platelet function is inhibited by clopidogrel mono-therapy indicates a pharmacologi-
cally relevant drug interaction.
Medication Subjects
#1 (wt/wt) #2 (wt/wt) #3 (wt/*2) #4 (wt/*2)
baseline normal normal normal normal 
(day 0) 85 u 79 u 89 u 101 u
clopidogrel mono-therapy inhibited inhibited normal inhibited
(day 7) 42 u 16 u 97 u 31 u
clopidogrel and omeprazole inhibited inhibited n.s.* normal
taken together (day 14) 44 u 10 u 74 u
clopidogrel and omeprazole n.s.* n.s.* n.s* normal
intake separated (day 21) 67 u
clopidogrel and rabeprazole n.s.* n.s.* n.s.* inhibited
taken together (day 28) 43 u
*n.s., not studied, according to protocol.
Fig.  1.  adP-induced  platelet  aggregation  in
four subjects treated with clopidogrel with and
without PPI co-therapy. the reference range of
the test was 53-122 u.
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function  of  subject  #3,  indicating  a  non-responder
status.  according  to  the  protocol,  no  further  tests
were performed.
In  subject  #4,  co-therapy  with  omeprazole  and
clopidogrel normalized platelet function, indicating a
relevant  drug  interaction.  this  interaction  was  not
abolished by separating the intake of the two drugs.
However, when rabeprazole was taken together with
clopidogrel, platelet aggregation was inhibited to the
range observed during clopidogrel mono-therapy.
dISCuSSIon
two of the four subjects (#1 and #2) carried only the
wild-type allele of CYP2C19. For both of them, co-
therapy with 20 mg of omeprazole did not diminish
the clopidogrel-induced inhibition of platelet aggrega-
tion, even when the drugs were taken simultaneously.
the clopidogrel–PPI interaction may therefore affect
only the subgroup of patients with genetic variants of
CYP2C19 and not the three quarters of the white Eu-
ropean population who are homozygous for the wild-
type CYP2C19 allele [9].
the  findings  in  subject  #2  suggest  that  an  acute
episode of diarrhoea may reduce the clopidogrel-in-
duced  inhibition  of  platelet  aggregation.  the  most
likely explanation is a reduction in gastrointestinal ab-
sorption  of  clopidogrel.  Considering  the  high  inci-
dence of acute viral enteritis and the importance of
dual antiplatelet therapy this phenomenon should be
studied in more detail.
Subject  #3  was  a  clopidogrel  non-responder,  al-
though she carried one wild-type allele. because about
25%  of  the  Caucasian  population  have  the  same
CYP2C19 allele status wt/*2 [9], a large proportion of
patients treated with clopidogrel may be non-respon-
ders. therefore, it seems reasonable to test the clopi-
dogrel-responder status of a patient who requires dual
anti-platelet  therapy  rather  than  genotyping  the  pa-
tient.
Subject  #4  revealed  the  most  important  findings.
the clopidogrel–omeprazole interaction was observed
in this patient with a predicted reduction in CYP2C19
function. Co-therapy with 20 mg of omeprazole com-
pletely abolished the clopidogrel-induced inhibition of
platelet  aggregation.  It  is  reasonable  to  assume  that
subjects  with  reduced  CYP2C19 function  are  at  in-
creased risk of this interaction. the interaction was
not  prevented  by  separating  the  intake  of  the  two
drugs  by  12  hours  (clopidogrel  in  the  morning,
omeprazole in the evening). However, the simultane-
ous intake of 10 mg of rabeprazole and clopidogrel
did not alter the effect of clopidogrel on platelet func-
tion. although only demonstrated in one subject, this
seems  to  indicate  that  the  interaction  between
omeprazole and clopidogrel may not be a class effect
of PPIs. this was also suggested by other studies [22-
25].
Rabeprazole was chosen for this study because 10
mg of this PPI is as potent as 20 mg of omeprazole
and more potent than 20 mg of pantoprazole in ele-
vating the intragastric pH [27]. Conversely, plasma lev-
els of rabeprazole after an intake of 10 mg are lower
than  those  measured  after  an  intake  of  20  mg  of
omeprazole or 20 mg of pantoprazole (these doses are
necessary for the prevention of peptic gastrointestinal
ulcer), minimizing the risk of a drug interaction with
clopidogrel [7].
although  these  observations  require  confirmation
in  much  larger  trials,  they  suggest  that  clopidogrel
should  not  be  combined  with  omeprazole  but  with
other PPIs, such as rabeprazole, if PPI co-therapy is
necessary  in  patients  receiving  clopidogrel  therapy.
this conclusion is consistent with the recommenda-
tions of the Fda and EMEa.
although the separation of the intake of clopido-
grel and omeprazole did not affect the interaction in
one subject, it is still reasonable to adopt this strategy
because  it  may  be  beneficial  in  other  subjects.  the
only possible disadvantage of such separated intake of
the two medications is reduced compliance. therefore,
patients must be informed of the importance of tak-
ing the medications.
Considering the high prevalence of patients taking
clopidogrel and aspirin and the need for gastroprotec-
tion, prospective randomized trials with clinical end-
points that examine the safest and most effective drug
regimen are highly warranted and should be undertak-
en in the near future. until more clinical data are pub-
lished, the prescription of a non-omeprazole PPI and
the separation of drug intake are preferable, although
the effect of separating the intake of the drugs is un-
substantiated.
Comment: this study was not supported from any pharma-
ceutical company and performed without any financial sup-
port.
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